Higher SAA1 levels under long-term HFD treatment could lead to extensive SAA1-derived amyloid deposits, which may consequently lead to the complications associated with HFD-induced obesity and metabolic disorders (Jang et al. 2016). Here, SAA1 is linked to Other metabolic disease.